The first half of 2024 was strong as M&As and financings dominate
Release Date:
Karen Carey, BioWorld managing editor and chief analyst, takes a look at the numbers from the first half of 2024. She finds the first six months to be healthy for the biopharma market while the rest of the year is populated with question marks that include the U.S. presidential election and potential interest rate cuts.
The first half of 2024 was strong as M&As and financings dominate